

Characterization of human cardiac mesenchymal stromal cells and their extracellular vesicles comparing with human bone marrow derived mesenchymal stem cells

In Sook Kang^{1,2,#}, Joowon Suh^{3,#}, Mi-Ni Lee³, Chaeyoung Lee^{3,4}, Jing Jin³, Changjin Lee⁵, Young Il Yang⁶, Yangsoo Jang^{1,7} & Goo Taeg Oh^{3,*}

¹The Graduate School, Yonsei University College of Medicine, Seoul 03722, ²Department of Internal Medicine, Mokdong Hospital, School of Medicine, Ewha Womans University, Seoul 07804, ³Department of Life Sciences and College of Natural Sciences, Ewha Womans University, Seoul 03760, Korea, ⁴Faculty of Arts and Science, University of Toronto, Toronto, ON M5S 1A1, Canada, ⁵Rosetta Exosome Inc., Seoul 06159, ⁶Paik Institute for Clinical Research, Inje University College of Medicine, Busan 47392, ⁷Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul 03722, Korea

Cardiac regeneration with adult stem-cell (ASC) therapy is a promising field to address advanced cardiovascular diseases. In addition, extracellular vesicles (EVs) from ASCs have been implicated in acting as paracrine factors to improve cardiac functions in ASC therapy. In our work, we isolated human cardiac mesenchymal stromal cells (h-CMSCs) by means of three-dimensional organ culture (3D culture) during *ex vivo* expansion of cardiac tissue, to compare the functional efficacy with human bone-marrow derived mesenchymal stem cells (h-BM-MSCs), one of the actively studied ASCs. We characterized the h-CMSCs as CD90^{low}, c-kit^{negative}, CD105^{positive} phenotype and these cells express NANOG, SOX2, and GATA4. To identify the more effective type of EVs for angiogenesis among the different sources of ASCs, we isolated EVs which were derived from CMSCs with either normoxic or hypoxic condition and BM-MSCs. Our *in vitro* tube-formation results demonstrated that the angiogenic effects of EVs from hypoxia-treated CMSCs (CMSC-Hpx EVs) were greater than the well-known effects of EVs from BM-MSCs (BM-MSC EVs), and these were even comparable to human vascular endothelial growth factor (hVEGF), a potent angiogenic factor. Therefore, we present here that CD90^{low} c-kit^{negative} CD105^{positive} CMSCs under hypoxic conditions secrete functionally superior EVs for *in vitro* angiogenesis. Our findings will allow more insights on

understanding myocardial repair. [BMB Reports 2020; 53(2): 118-123]

INTRODUCTION

Cardiovascular disease (CVD) is a global major health problem and has remained a leading cause of death, despite the advances in the current medical technologies (1). Cardiovascular regeneration (CVR) with adult stem-cell (ASC) therapy is a promising field for addressing advanced CVD (2, 3). Although there are diverse origins of ASCs, the cells that are mostly studied for CVR are mesenchymal stem cells (MSCs) and cardiac stem cells (4). Given the salutary effects of the ASCs for CVD reported by previous studies, there have been many preclinical studies as well as clinical trials conducted with the ASCs (4, 5).

The putative 'cardiac stem/progenitor cell (CS/CPC)' is also called a cardiac mesenchymal stem cell, cardiac interstitial cell, cardiac mesenchymal stromal cell (CMSC), or cardiosphere-derived cell (CDC). These cells are usually obtained from the right ventricular septum through cardiac biopsy, or from a left atrial sample of cardiac surgery (6, 7). In particular, CDCs indicate the cells derived from cardiospheres; multicellular clusters formed from the primary culture of cardiac specimen. There are several issues about CVR using different types of CS/CPCs. Especially, based on the research that c-kit⁺ cells were potential CS/CPCs for rejuvenating heart muscles in mice (8), many researchers had considered these cells to be CS/CPCs. However, recent studies have proved that c-kit⁺ cells are only a small proportion of CDCs, have low regenerative potential, and originate from cardiac endothelial cells, rather than from CS/CPCs (9, 10). Another issue is about CD90, which was originally discovered as a thymocyte antigen (thy-1) and can be used as a marker for a variety of stem cells and fibroblasts. Despite limited information regard-

*Corresponding author. Tel: +82-2-3277-4128; Fax: +82-2-3277-3760; E-mail: gootaeg@ewha.ac.kr

#These authors contributed equally to this work.

<https://doi.org/10.5483/BMBRep.2020.53.2.235>

Received 27 September 2019, Revised 28 October 2019,
Accepted 28 October 2019

Keywords: Cardiovascular disease, Extracellular vesicles, Mesenchymal stem cell, Regeneration

ing CD90 in CVR, several studies proved that CD90⁻ CPCs expressed the genes related to stemness and could differentiate into mature cardiomyocytes with complete sarcomere formation (9, 11, 12). Although these cells also showed a greater regenerative potential in myocardial infarction (MI), it is still unclear which types of CS/CPCs are more important to the CVR.

Recently, another important concept has been receiving attention in ASC therapy; the paracrine effect. Many studies showed that the cardiac functional advances were not the direct effects of the transplanted CS/CPCs themselves. Instead, such improvement seemed to be induced by means of paracrine factors (13, 14); the extracellular vesicle (EV) is one strong candidate (15-17). EVs, also known as exosomes, are nanosized vesicles encompassed by lipid bilayer with diameters from 30-130 nm. EVs exist in almost all biological fluids, including blood, urine, and cell culture medium. They are released from the cells when multivesicular bodies fuse with the cell membrane. They participate as cellular cargos by carrying genetic materials and proteins, facilitate intercellular communication (16), and have specificity that depends on their originating cells (15). EVs from CDCs could inhibit apoptosis, promote proliferation of cardiomyocytes, and improve cardiac functions in MI mouse models by means of some miRNAs (18, 19).

In this study, we first compared the characterization of h-CMSCs and h-BM-MSCs, and identified EVs from the media of the cells. Relatively few studies have compared the effects of these cells directly (20-22), and especially CD90^{low}, c-kit^{negative} CS/CPCs need to be further investigated. To compare the effects of EVs from each cell group, we evaluated *in vitro* effects of EVs on angiogenesis. Therefore, the

comparative studies regarding EVs of h-BM-MSCs and h-CMSCs with normoxic and hypoxic conditions would help decide on future effective therapeutic target.

RESULTS

Characterization of h-BM-MSCs and h-CMSCs

To characterize the cultured h-BM-MSCs and h-CMSCs, we analyzed various cell surface markers for hematopoietic or cardiac cells by flow cytometry (Fig. 1A). Expression of a cluster of differentiation (CD)45, a type I transmembrane protein that is present in various isoforms on differentiated hematopoietic cells, is less than 1% in both cell populations. Another hematopoietic stem-cell marker, CD34, is expressed only 1.87% in CMSCs and 6.09% in BM-MSCs, which meant that these cells are a CD45 and CD34 negative cell population, as previously reported (23). Importantly, CD90 is differently expressed in each cell population; 82.1% of BM-MSCs vs. 26.3% of CMSCs, which is similar to CDCs described (22). Both BM-MSCs and CMSCs express CD105 in about 80% of the cell population. CD105 (Endoglin), a membrane glycoprotein and a part of the TGF β receptor complex, plays a critical role in neoangiogenesis. CD117, known also as c-kit, is a stem-cell growth factor receptor on the surface of hematopoietic stem cells and some cancer cells. Expression levels of CD117 are less than 1% in both cell groups.

To further define the characteristics of the cells, we did RT-PCR assays for various marker genes. NANOG and SOX2, the transcriptional factors of embryonic stem cells, were expressed in all three cell populations (Fig. 1B). For cardiac markers, mRNAs of NKX2-5 and myosin heavy chain, the α isoform (MYH6), were not noticeable in all groups, but the expression of GATA4, a cardiac-specific transcription factor for proper mammalian cardiac development, was prominent in




Fig. 1. Characterization of the cells. (A) Flow cytometry results showed negative expression of CD117 and CD45, low expression of CD34, positive expression of CD105, and different expression of CD90 in the BM-MSCs and CMSCs. (B) RT-PCR analysis showed that the mRNA expression levels of NANOG, SOX2 in BM-MSCs, CMSC-Nx, and CMSC-Hpx were high, whereas the levels were hardly detectable for NKX2-4 and MYH6. The expression of GATA4 was detected only in CMSCs.




Fig. 2. Morphology and size of EVs. (A) Transmission electron microscopy showed about 100 nm of round EVs with a cup shape in each group. DLS analysis measured the size distributions (B) and the NTA demonstrated the high particle concentrations corresponding vesicle sizes, and the good purity (C).

CMSCs but not in BM-MSCs (Fig. 1B). GATA4 and NKX2-5 are early markers of precardiac cells and present synergism as cofactors (24). GATA4 is expressed in CS/CPCs followed by the expression of NKX2-5 and ISL1 of the cardiac mesoderm.

Characterization of EVs isolated from CMSCs and BM-MSCs

EVs were isolated from conditioned media from each cell population. Transmission electron microscopy showed that EVs exhibited umbilicated round morphologies (Fig. 2A). Size measurements by dynamic light-scattering (DLS) analysis found a size of 95-115 nm for EVs (Fig. 2B). CMSC-Hpx EVs are slightly larger than the EVs from normoxia-conditioned CMSCs (CMSC-Nx) (Fig. 2A, B), which was similar to a previous report (21). Nanoparticle tracking analysis (NTA) confirmed the size distribution of EVs and showed sufficient particle concentration (Fig. 2C). The purities of isolated EVs were analyzed by a size exclusion chromatography with high-performance liquid chromatography (HPLC) system, which exhibited levels of contaminating substances smaller than EVs were less than 5% in all EV preparations (Fig. 3A). Immunoblotting analysis have shown the enrichment of EV surface markers tetraspanins (CD9, CD63, and CD81) with minor differences at expression levels (Fig. 3B), while H2B histone, one of common contaminants in EV preparation was not detected in all isolated EVs used in this study (Fig. 3B).

CMSC-Hpx EVs exhibit functional superiority on *in vitro* angiogenesis

To evaluate the effects of EVs on angiogenesis, we did a tube-formation assay with HUVECs (human umbilical vein endothelial cells). HUVECs were cultured with hVEGF (positive control), BM-MSC EVs, CMSC-Nx EVs, or CMSC-Hpx EVs, and these were compared with the cells with media only (negative control; NC). HUVECs treated with BM-MSC EVs and CMSC-Hpx EVs showed tube formation significantly better than did HUVECs with NC at 6 h (Fig. 4), whereas CMSC-Nx




Fig. 3. Purity analysis and markers for EVs. (A) Purity analysis by HPLC showed about 95% of elutes were within 5 min, which represented EV fractions in BMSCs and CMSCs. The small peak at 8 min contains substances with small molecular weight. (B) Immunoblotting analysis against EV surface markers, CD9, CD63, and CD81 on EV groups and whole cell lysates. H2B, histone, one of common contaminating substance in EV preparation, was not detected in all isolated EVs.

EVs failed to demonstrate superiority over NC in tube formation. The formation of tube-like structures was increased with time up to 6 h in all groups of experiments. Interestingly, the tube-like structures lasted for 8 h in the cells treated with VEGF or CMSC-Hpx, whereas these structures started to collapse around 8 h in the group of BM-MSC EVs (Fig. 4B, C). With our results, CMSC-Nx EVs did not show improvement in tube formation, and only CMSC-Hpx EVs were able to improve the tube formation, creating tube-like structures that persisted for 8 h, all of which were comparable to the effect of VEGF.

DISCUSSION

We used the CMSCs obtained by *ex vivo* expansion of human heart tissue using 3D culture as previously described (25). These CMSCs did not form cardiospheres, but shared similar phenotypes with CDCs of CD90^{low}, c-kit^{negative}, CD105^{positive}. The CMSCs were distinguished from MSCs in the expression of CD90 (22).

Recently, a decision has been made on an issue concerning the regeneration of CS/CPCs, especially c-kit⁺ cells (6, 8, 26): 31 papers from a researcher at the Harvard lab studying the role of c-kit⁺ cells as potential CS/CPCs were retracted




Fig. 4. Tube-formation assay of HUVECs treated with three types of EVs. (A) Microscopy images were taken for the tube-formation assay of HUVECs at 6 h. Endothelial growth media was used for a negative control (NC) and VEGF (20 ng/ml) was used for positive control; Cells were treated with media including EVs from BM-MSCs, CMSC-Nx, or CMSC-Hpx for experiments. Detailed methods are described in the supplemental materials. (B) Total tube length at 6 h showed the augmented tube formation in the groups treated with VEGF, BM-MSC EVs, or CMSC-Hpx EVs; *P < 0.01, **P < 0.001 vs. NC, ns = no significance; ANOVA followed by Turkey post hoc analysis. (C) The tube-like structure was sustained until 8 h in VEGF and CMSC-Hpx EVs; *P < 0.05, **P < 0.01; student t-test within group at 6 h and 8 h.

because of 'the inclusion of fabricated and/or falsified data' and the ongoing clinical trials involving these cells were paused (27, 28). Many scientists say that it is time to reset the putative CS/CPC research, although there are some researchers saying that c-kit⁺ cells are still valid for further analysis of regeneration effects based on some animal study results (28, 29). However, it was known that c-kit⁺ cells are only a minor fraction of the whole CDC from previous reports (22), and these cells barely differentiate into cardiomyocytes. Moreover, the remnant c-kit⁺ cells in the heart are regarded as cardiac endothelial cells rather than as CS/CPCs (30). Retrospective analysis of a recently completed clinical trial (CADUCEUS) demonstrated that c-kit expression was not related to the therapeutic effect of CDCs in humans, and that c-kit⁺ cells were functionally inferior to unsorted human CDCs (9). Given these previous studies, our study tested the idea that CS/CPCs with low c-kit expression may secrete paracrine factors by means of EVs to promote angiogenesis. In our study, both BM-MSCs and CMSCs hardly expressed c-kit.

Meanwhile, CMSCs and BM-MSCs are distinguished by CD90 expression, and unlike BM-MSCs, CMSCs expressed only 26% of CD90. Li *et al.* also reported a similar profile of gene expression: the expression of CD90 as 18.4% in CDCs, compared with an expression of 99.0% in BM-MSCs (22). Thy-1 knock-out mice are viable and grossly normal (31), and the definite roles of CD90⁻ clones in CVR are not clear, but some researchers reported data regarding this topic. They demonstrated the superiority of CD90⁻ CDCs over CD90⁺ CDCs (9, 11, 12). In the chronic MI rat model, injection of CD90⁻ CMSCs augmented cardiac function outperforming CD90⁺ cells, and histological analysis of CD90⁻ cells revealed an increase in vascularization within the infarct lesion (12). Other studies reported similar salutary effects, since CD90⁻ cells secrete less inflammatory cytokines and may differentiate into cardiomyocytes (9). Interestingly, CD90⁻ cells expressed significantly more hepatocyte growth factor (HGF) than did CD90⁺ cells, and both CD90⁻ and CD90⁺ CMSCs secrete VEGF or basic fibroblast growth factor (bFGF) comparably (12).

By means of the transcriptional profiles and gene ontology enrichment analysis of adult human CDCs subdivided by the expression of CD90, CD90⁻ clones were enriched with the genes related to stemness, whereas CD90⁺ clones were enriched with fibroblast-associated genes (11). Two separate studies found that the expression level of CD90/THY-1 changes dynamically at the formation of cardiospheres under different culture conditions (11, 32). Our CMSCs were isolated as CD90^{low} CS/CPCs under specific culture condition to promote stemness (25).

Hence, our CD90^{low} c-kit^{negative} CD105^{positive} CMSCs are likely to play a significant role in the regeneration of the heart as an active fraction. Most research with CS/CPCs has been done with CDCs of heterogeneous populations or with c-kit⁺ cells, so far. Therefore, further studies with c-kit^{negative} and

CD90^{negative} clones are needed to reveal the more effective therapeutic application of CS/CPC and would be helpful for understanding the roles of these cells.

GATA4 is one of the earliest transcription factors and a critical regulator of cardiac development, and interacts with many transcriptional factors, such as NKX2-5 (33, 34). Although GATA4 is crucial for regulating the expression of NKX2-5, it has been proposed that additional signaling pathways are needed for the initial activation of NKX2-5 (34, 35). In our results, CMSCs expressed only GATA4, but not NKX2-5. Other studies using CS/CPCs from rotating tissue-culture conditions similar to our work, have also reported that GATA4 is expressed with limited expression of NKX2-5, which proposed these cells in early developmental stages (11, 36). Therefore, our cells may also be considered to be in early developmental stages before expressing NKX2-5, and further analysis will help us understand the roles of CS/CPCs at various developmental stages or marking various kinds of stemness during primary culture.

Our results showed that CMSC-Hpx EVs improved tube formation, but CMSC-Nx EVs did not. EV release from hypoxic MSCs was associated with an increased hypoxia-inducible factor 1- α activation, which could increase angiogenesis through Jagged-1 (37, 38). Hypoxia-treated EVs from human adipose-derived MSCs were reported to activate the protein kinase A signaling pathway and promote the expression of VEGF (20). EVs from hypoxic CDCs (CD90^{high} cells) were reported to contain the increased level of EV-associated miRNAs and improved the tube formation of HUVECs (21). A study using EVs from CPC-Hpx (c-kit⁺) reported the improvement of rat cardiac function and hypertrophy (14). These imply that tube formation of CD90^{low} c-kit^{negative} CMSC EVs under hypoxia was increased by triggering such signaling pathways. Further studies with our CD90^{low} c-kit^{negative} CMSCs will add valuable insights on understanding the extracellular vesicular influence of these cells in hypoxic conditions. The clinical potential of EVs could greatly depend on the cell-culture environment. Further research is needed to examine how CMSCs under hypoxic conditions could produce more effective EVs. In earlier works, growth factors including HGF, VEGF, and bFGF were reported to be related to these functional differences between CDCs and MSCs (22) and between the CD90⁻ and CD90⁺ CDCs (12). Since EVs have been reported to contain various growth factors, it is very likely that the more effective function of CMSC-Hpx EVs in our study resulted from the secretion of EVs with growth factors like HGF.

There are several questions to be answered by future research with EVs from CMSCs. First, the yield of EVs from CMSCs was lower than the yield of BM-MSCs EVs (Supplementary Fig. 1). CMSC-EV tended to be more clingy, possibly because of the different nature of EVs, than were BM-MSCs EVs, which may have caused unpredictable frequent loss during the EV isolation. Therefore, it was difficult to

obtain sufficient EVs from CMSCs of our limited human samples. These technical problems should be solved for further experiments.

Second, the degree of tube formation was not increased in proportion to the concentration of EVs. Instead, the effect was best at the dose of 2 µg/ml (0.4 µg/well) of EVs in all three groups, but was decreased with a higher concentration of EVs (Supplementary Fig. 2). There have been reports of biphasic results of tube augmentation with increasing concentration of EVs, although others demonstrated that angiogenesis increases dose-dependently with EVs treatment (21, 39). Additionally, they used ten times more EV concentration than were used in our work (25 µg/ml versus 2 µg/ml). These differences between different laboratories could have resulted for various technical reasons, such as different isolation methods, the purity of EVs, and different cell-culture environments. Controlling the detailed cell-culture condition and the standardized isolation methods of EVs are needed to solve the quality and quantity differences of EVs.

Our study showed that the hypoxic condition of CD90^{low}c-kit^{negative} CMSCs could increase the secretion of EVs with active components for angiogenesis. These imply the functional importance of CD90^{low}c-kit^{negative} CMSCs, which has often been underestimated in the CVD. Therefore, our results would help us understand the role of CD90^{low}c-kit^{negative} cardiac cells and apply their EVs clinically to cardiac regeneration after CVD. Further investigations are needed to define the mechanism and the functional characterization of CMSC-Hpx EVs.

MATERIALS AND METHODS

Details are provided in the Supplementary materials.

Human CMSCs preparation

CMSCs were explanted from cadaveric tissue and expanded as described previously (25). Briefly, after 14 d of dynamic tissue culture, outgrown cells were collected and suspended in growth-culture media for a conventional monolayer culture condition. When cells reached 80% confluence, they were detached and subcultured. Experiments were approved by the institutional review board of Busan Paik Hospital (IRB No. 2016-11-0006).

ACKNOWLEDGEMENTS

This research was supported by a grant from the Korean Health Technology R&D Project through the Korean Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI15C1277).

CONFLICTS OF INTEREST

The authors have no conflicting interests.

REFERENCES

1. Benjamin EJ, Muntner P, Alonso A et al (2019) Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. *Circulation* 139, e56-e528
2. Cambria E, Pasqualini FS, Wolint P et al (2017) Translational cardiac stem cell therapy: advancing from first-generation to next-generation cell types. *NPJ Regen Med* 2, 17
3. Makkar RR, Smith RR, Cheng K et al (2012) Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. *Lancet* 379, 895-904
4. Parizadeh SM, Jafarzadeh-Esfehani R, Ghandehari M et al (2019) Stem cell therapy: A novel approach for myocardial infarction. *J Cell Physiol* 234, 16904-16912
5. Yun CW and Lee SH (2019) Enhancement of Functionality and Therapeutic Efficacy of Cell-Based Therapy Using Mesenchymal Stem Cells for Cardiovascular Disease. *Int J Mol Sci* 20, 982
6. Barile L, Messina E, Giacomello A and Marban E (2007) Endogenous cardiac stem cells. *Prog Cardiovasc Dis* 50, 31-48
7. Smith RR, Barile L, Cho HC et al (2007) Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. *Circulation* 115, 896-908
8. Beltrami AP, Barlucchi L, Torella D et al (2003) Adult Cardiac Stem Cells Are Multipotent and Support Myocardial Regeneration. *Cell* 114, 763-776
9. Cheng K, Ibrahim A, Hensley MT et al (2014) Relative roles of CD90 and c-kit to the regenerative efficacy of cardiosphere-derived cells in humans and in a mouse model of myocardial infarction. *J Am Heart Assoc* 3, e001260
10. Gude NA and Sussman MA (2018) Chasing c-Kit through the heart: Taking a broader view. *Pharmacol Res* 127, 110-115
11. Gago-Lopez N, Awaji O, Zhang Y et al (2014) THY-1 receptor expression differentiates cardiosphere-derived cells with divergent cardiogenic differentiation potential. *Stem Cell Reports* 2, 576-591
12. Shen D, Shen M, Liang H et al (2018) Therapeutic benefits of CD90-negative cardiac stromal cells in rats with a 30-day chronic infarct. *J Cell Mol Med* 22, 1984-1991
13. Eschenhagen T, Bolli R, Braun T et al (2017) Cardiomyocyte Regeneration. *Circulation* 136, 680-686
14. Agarwal U, George A, Bhutani S et al (2017) Experimental, Systems, and Computational Approaches to Understanding the MicroRNA-Mediated Reparative Potential of Cardiac Progenitor Cell-Derived Exosomes From Pediatric Patients. *Circ Res* 120, 701-712
15. Bei Y, Das S, Rodosthenous RS et al (2017) Extracellular Vesicles in Cardiovascular Theranostics. *Theranostics* 7,

- 4168-4182
16. Ibrahim A and Marban E (2016) Exosomes: Fundamental Biology and Roles in Cardiovascular Physiology. *Annu Rev Physiol* 78, 67-83
 17. Zamani P, Fereydouni N, Butler AE, Navashenq JG and Sahebkar A (2018) The therapeutic and diagnostic role of exosomes in cardiovascular diseases. *Trends Cardiovasc Med* 29, 313-323
 18. Ibrahim Ahmed GE, Cheng K and Marbán E (2014) Exosomes as Critical Agents of Cardiac Regeneration Triggered by Cell Therapy. *Stem Cell Reports* 2, 606-619
 19. Sahoo S and Losordo DW (2014) Exosomes and cardiac repair after myocardial infarction. *Circ Res* 114, 333-344
 20. Xue C, Shen Y, Li X et al (2018) Exosomes Derived from Hypoxia-Treated Human Adipose Mesenchymal Stem Cells Enhance Angiogenesis Through the PKA Signaling Pathway. *Stem Cells Dev* 27, 456-465
 21. Namazi H, Mohit E, Namazi I et al (2018) Exosomes secreted by hypoxic cardiosphere-derived cells enhance tube formation and increase pro-angiogenic miRNA. *J Cell Biochem* 119, 4150-4160
 22. Li TS, Cheng K, Malliaras K et al (2012) Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. *J Am Coll Cardiol* 59, 942-953
 23. Maleki M, Ghanbarvand F, Reza Behvarz M, Ejtemaei M and Ghadirkhomi E (2014) Comparison of mesenchymal stem cell markers in multiple human adult stem cells. *Int J Stem Cells* 7, 118-126
 24. Durocher D, Charron F, Warren R, Schwartz RJ and Nemer M (1997) The cardiac transcription factors Nkx2-5 and GATA-4 are mutual cofactors. *EMBO J* 16, 5687-5696
 25. Kim JT, Chung HJ, Seo JY et al (2015) A fibrin-supported myocardial organ culture for isolation of cardiac stem cells via the recapitulation of cardiac homeostasis. *Biomaterials* 48, 66-83
 26. van Berlo JH, Kanisicak O, Maillet M et al (2014) c-kit+ cells minimally contribute cardiomyocytes to the heart. *Nature* 509, 337-341
 27. G K Harvard calls for retraction of dozens of studies by noted cardiac researcher. <https://www.nytimes.com/2018/10/15/health/piero-anversa-fraud-retractions.html>. Published October 15, 2018. Accessed September 25, 2019.
 28. Kaiser J (2018) Suspect science leads to pause in stem cell trial. *Science* 362, 513
 29. Epstein JA (2019) A Time to Press Reset and Regenerate Cardiac Stem Cell Biology. *JAMA Cardiol* 4, 95-96
 30. Sultana N, Zhang L, Yan J et al (2015) Resident c-kit(+) cells in the heart are not cardiac stem cells. *Nat Commun* 6, 8701
 31. Rege TA and Hagood JS (2006) Thy-1, a versatile modulator of signaling affecting cellular adhesion, proliferation, survival, and cytokine/growth factor responses. *Biochim Biophys Acta* 1763, 991-999
 32. Forte E, Miraldi F, Chimenti I et al (2012) TGFbeta-dependent epithelial-to-mesenchymal transition is required to generate cardiospheres from human adult heart biopsies. *Stem Cells Dev* 21, 3081-3090
 33. Heikinheimo M, Scandrett JM and Wilson DB (1994) Localization of transcription factor GATA-4 to regions of the mouse embryo involved in cardiac development. *Dev Biol* 164, 361-373
 34. Yilbas AE, Hamilton A, Wang Y et al (2014) Activation of GATA4 gene expression at the early stage of cardiac specification. *Front Chem* 2, 12
 35. Akazawa H and Komuro I (2005) Cardiac transcription factor Csx/Nkx2-5: Its role in cardiac development and diseases. *Pharmacol Ther* 107, 252-268
 36. Oldershaw R, Owens WA, Sutherland R et al (2019) Human Cardiac-Mesenchymal Stem Cell-Like Cells, a Novel Cell Population with Therapeutic Potential. *Stem Cells Dev* 28, 593-607
 37. Lo Sicco C, Reverberi D, Balbi C et al (2017) Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: endorsement of macrophage polarization. *Stem Cells Transl Med* 6, 1018-1028
 38. Hernán GK, Nahuel AG, Imelda O et al (2017) Hypoxia inducible factor-1apotentiated jagged1-mediated angiogenesis by mesenchymal stemcell-derived exosome. *Stem Cells* 35, 1747-1759
 39. Gray WD, French KM, Ghosh-Choudhary S et al (2015) Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. *Circ Res* 116, 255-263